Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews

被引：0
|
作者：
Sharea Ijaz
Blanca Bolea
Simon Davies
Jelena Savović
Alison Richards
Sarah Sullivan
Paul Moran
机构：
[1] University of Bristol,Bristol Medical School
[2] National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) West,Centre for Addiction and Mental Health (CAMH)
[3] University of Toronto,undefined
来源：
BMC Psychiatry | / 18卷
关键词：
Schizophrenia; Antipsychotics; Diabetes mellitus; Metabolic syndrome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews
    Davies, Laurie E.
    Spiers, Gemma
    Kingston, Andrew
    Todd, Adam
    Adamson, Joy
    Hanratty, Barbara
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2020, 21 (02) : 181 - 187
  • [32] Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
    Boiko, Anastasiia S.
    Mednova, Irina A.
    Kornetova, Elena G.
    Goncharova, Anastasiia A.
    Semke, Arkadiy, V
    Bokhan, Nikolay A.
    Ivanova, Svetlana A.
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (10):
  • [33] Antipsychotic polypharmacy in treatment-resistant schizophrenia
    Dugan, DJ
    Vertrees, JE
    Saklad, SR
    Richards, AM
    Ereshefsky, L
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 278 - 278
  • [34] Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
    Yasui-Furukori, Norio
    Shimoda, Kazutaka
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2020, 40 (03) : 208 - 210
  • [35] Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
    Lahteenvuo, Markku
    Tiihonen, Jari
    DRUGS, 2021, 81 (11) : 1273 - 1284
  • [36] Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale
    Azorin, Jean-Michel
    Simon, Nicolas
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (12) : 1175 - 1186
  • [37] Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
    Markku Lähteenvuo
    Jari Tiihonen
    Drugs, 2021, 81 : 1273 - 1284
  • [38] REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
    Leucht, Stefan
    Samara, Myrto
    Rodolico, Alessandro
    Bauer, Ingrid
    Baeckers, Lio
    Bighelli, Irene
    SCHIZOPHRENIA BULLETIN, 2020, 46 : S116 - S116
  • [39] Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan
    Qiu, Hong
    He, Yong
    Zhang, Yongjing
    He, Minfu
    Liu, Jin
    Chi, Rui
    Si, Tianmei
    Wang, Huaning
    Dong, Wentian
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 (12): : 1202 - 1212
  • [40] Antipsychotic treatment in elderly patients on polypharmacy with schizophrenia
    Stuhec, Matej
    CURRENT OPINION IN PSYCHIATRY, 2022, 35 (05) : 332 - 337
12345